Literature DB >> 26206986

[Phage associated polysaccharide depolymerases - characteristics and application].

Agnieszka Maszewska1.   

Abstract

Bacteriophages have been of interest as agents combating undesirable bacteria since their discovery nearly 100 years ago. Currently, intensive research is being conducted into two groups of phage enzymes, which cause damage to bacterial cells. The first group includes lysins responsible for breaking down the cell wall in order to release progeny phages and the second is polysaccharides depolymerases (PDs), which degrade capsular and structural polysaccharides, including exopolysaccharides (EPS) - a dominant bacterial biofilm component. PDs can be attached to a phage tail or present as a free form diffused to the medium, their production takes place constitutively or is induced by the polysaccharide presence. PDs belong to two groups of enzymes: hydrolases (glycanases) or polysaccharide lyases. These enzymes are a very heterogeneous group with regard to substrate specificity, the molecular weight or sensitivity bakteriofato physical and chemical factors. Phages producing PDs act against encapsulated infectious bacteria and have a great potential as a new class of anti-biofilm agents. Polysaccharide depolymerases depriving bacteria of the capsule, reduce their virulence and sensitize them to the immune system. The variety of biofilms forming bacteria and exopolysaccharides produced by them requires the use of specific phages producing DP. The problem of DP and phages specificity can be solved by using phage cocktails or introducing into the virus genome genes encoding enzymes degrading various bacterial exopolysaccharides important in the biofilm formation or broadening the host range. The use of DP or a DP-producing phage combined with other antibiofilm agents brings promising results. This indicates a direction for further research to develop effective methods to combat bacterial biofilms. Phage-borne PDs can be used for determination of the bacterial polysaccharides structure or efficient capsular typing.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26206986     DOI: 10.5604/17322693.1157422

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  8 in total

Review 1.  In Vivo Bacteriophages' Application for the Prevention and Therapy of Aquaculture Animals-Chosen Aspects.

Authors:  Patrycja Schulz; Joanna Pajdak-Czaus; Andrzej Krzysztof Siwicki
Journal:  Animals (Basel)       Date:  2022-05-10       Impact factor: 3.231

Review 2.  Bacteriophage-Derived Depolymerases against Bacterial Biofilm.

Authors:  Gracja Topka-Bielecka; Aleksandra Dydecka; Agnieszka Necel; Sylwia Bloch; Bożena Nejman-Faleńczyk; Grzegorz Węgrzyn; Alicja Węgrzyn
Journal:  Antibiotics (Basel)       Date:  2021-02-10

3.  Identification of a Depolymerase Specific for K64-Serotype Klebsiella pneumoniae: Potential Applications in Capsular Typing and Treatment.

Authors:  Jiayin Li; Yueying Sheng; Ruijing Ma; Mengsha Xu; Fuli Liu; Rong Qin; Mingxi Zhu; Xianchao Zhu; Ping He
Journal:  Antibiotics (Basel)       Date:  2021-02-01

4.  The Bacteriophage vB_CbrM_HP1 Protects Crucian Carp Against Citrobacter braakii Infection.

Authors:  Chunzheng Huang; Chao Feng; Xiao Liu; Rihong Zhao; Zijing Wang; Hengyu Xi; Hongda Ou; Wenyu Han; Zhimin Guo; Jingmin Gu; Lei Zhang
Journal:  Front Vet Sci       Date:  2022-05-06

5.  Cloning and Characterization of a Thermostable Endolysin of Bacteriophage TP-84 as a Potential Disinfectant and Biofilm-Removing Biological Agent.

Authors:  Joanna Żebrowska; Olga Żołnierkiewicz; Małgorzata Ponikowska; Michał Puchalski; Natalia Krawczun; Joanna Makowska; Piotr Skowron
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

6.  Improving Phage-Biofilm In Vitro Experimentation.

Authors:  Stephen T Abedon; Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Matthew B Sullivan
Journal:  Viruses       Date:  2021-06-19       Impact factor: 5.048

Review 7.  Filamentous Bacteriophage-A Powerful Carrier for Glioma Therapy.

Authors:  Yicun Wang; Jiyao Sheng; Jin Chai; Cuilin Zhu; Xin Li; Wei Yang; Ranji Cui; Tongtong Ge
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

Review 8.  Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.

Authors:  Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Stephen T Abedon
Journal:  Antibiotics (Basel)       Date:  2021-12-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.